Families Say Animal Studies Back Their Claims In Zofran MDL

Law360, New York (January 6, 2016, 3:38 PM EST) -- Families who claim that GlaxoSmithKline’s “off label” promotion of its anti-nausea drug Zofran for morning sickness led to birth defects urged the Massachusetts federal judge overseeing the multidistrict litigation on Wednesday not to dismiss their claims, pointing to animal studies they say support their allegations.

The families told U.S. District Judge F. Dennis Saylor IV that GlaxoSmithKline LLC’s motion to dismiss all of their more than 200 cases is premature, as no discovery has yet been undertaken, and since the U.S. Food and Drug Administration hasn’t approved Zofran to treat morning sickness, only GSK has control over the relevant evidence of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS